Gerresheimer (ETR:GXI) Trading Up 0.1% - Here's What Happened

Key Points

• Gerresheimer AG's stock price increased by 0.1% during mid-day trading, reaching a last traded price of €37.98 ($44.16).
• The company has a current market capitalization of $1.30 billion and a PE ratio of 11.38.
• Gerresheimer specializes in manufacturing medicine packaging and drug delivery devices through its three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies.

Gerresheimer AG (ETR:GXI - )'s stock price was up 0.1% during mid-day trading on Tuesday . The stock traded as high as €38.32 ($44.56) and last traded at €37.98 ($44.16). Approximately 265,963 shares traded hands during mid-day trading, an increase of 89% from the average daily volume of 140,925 shares. The stock had previously closed at €37.96 ($44.14).

Gerresheimer Price Performance

The company has a debt-to-equity ratio of 87.94, a current ratio of 0.80 and a quick ratio of 0.40. The company has a 50-day moving average price of €42.44 and a 200-day moving average price of €50.56. The firm has a market capitalization of $1.30 billion, a PE ratio of 11.38, a P/E/G ratio of 0.82 and a beta of 0.94.

Gerresheimer Company Profile

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.